LGND – ligand pharmaceuticals incorporated (US:NASDAQ)
Stock Stats
News
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? [Yahoo! Finance]
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Royal Bank Of Canada from $234.00 to $235.00. They now have an "outperform" rating on the stock.
Ligand Pharmaceuticals (NASDAQ:LGND) had its price target raised by analysts at Stifel Nicolaus from $220.00 to $230.00. They now have a "buy" rating on the stock.
Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
Form 4 LIGAND PHARMACEUTICALS For: Feb 02 Filed by: KOZARICH JOHN W
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
Form 4 LIGAND PHARMACEUTICALS For: Jan 02 Filed by: KOZARICH JOHN W
Form 4 LIGAND PHARMACEUTICALS For: Dec 31 Filed by: Espinoza Octavio
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.